Krüppel-like factor 1 (KLF1/EKLF) is a transcription factor that globally activates genes involved in erythroid cell development. Various mutations are identified in the human KLF1 gene. The E325K mutation causes congenital dyserythropoietic anemia (CDA) type IV, characterized by severe anemia and non-erythroid-related symptoms. The CDA mutation is in the second zinc finger of KLF1 at a position functionally involved in its interactions with DNA. The molecular parameters of how CDA-KLF1 exerts its biological effects have not been addressed. Here, using an in vitro selection strategy we determined the preferred DNA-binding site for CDA-KLF1.
Introduction
Krüppel-like Factor 1 (KLF1/EKLF) is an erythroid specific transcription factor essential for red blood cell development (1, 2) . It has a typical modular structure for transcription factors with its transactivation domain at the N-terminus and three zinc fingers (C2H2) generating its DNA binding domain at the Cterminus. KLF1 belongs to the KLF family of transcription factors that binds the G-rich strand of socalled CACCC-box motifs located in regulatory regions of numerous erythroid genes. KLF1 is involved in activation of globins, globin chaperons, cytoskeleton and membrane proteins, ion and water channels, iron metabolism and heme synthesis enzymes and cell cycle regulators (3, 4) . Mouse knockout studies have shown that KLF1 ablation is embryonic lethal at day E 14.5 (5, 6) . KLF1 exerts its function by interacts with chromatin-modifying and -remodeling factors, such as P/CAF, CBP/p300, and the SWI/SNF complex (7-9,reviewed in 10) that help to coordinate opening of chromatin structure, for example at the β-like globin locus (11) . Furthermore, KLF1 functions are regulated by various posttranslational modifications such as phosphorylation (12) , sumoylation (13) , acetylation (7, 14) , and ubiquitination (15) .
The importance of KLF1 for human erythropoiesis is supported by the hematologic diseases and disorders that arise due to mutations occurring along the whole KLF1 gene. These mutations lead to a range of phenotypic pathology from benign to severe (16, 17) . Some mutations in KLF1 lead to haploisufficiency that affects expression of certain genes (Lu/BCAM, Bcl11A, HBD) that are highly sensitive to KLF1 expression levels. These effects are observed in Hereditary Persistence of Fetal Hemoglobin (HPFH) or the rare In(Lu) blood type (18) (19) (20) .
The mutations causing the most severe phenotypes affect functionally important amino acids. Two examples of such monoallelic mutations have been described. They substitute the amino acids in the zinc finger DNA binding domain at positions that are involved in direct interactions with regulatory elements of KLF1's target genes. These mutations alter the properties of the protein such that it acquires novel dominant characteristics (reviewed in: 17, 21) . They adjust its ability to recognize and bind novel target DNA sequences and lead to serious transcriptional consequences. In both described cases KLF1 mutations are responsible for development of severe anemia. One, found in the mouse and called Nan-KLF1, leads to hemolytic neonatal anemia with Hereditary Spherocytosis (22) (23) (24) . The second is found in humans and leads to Congenital Dyserythropoietic Anemia type IV (CDA IV) (25,26).
The mouse mutation (E339D), although conservative, on the one hand limits recognition of the normal set of WT-KLF1 targets, but on the other hand leads to acquisition of a novel ability to recognize neomorphic genes not normally activated by WT-KLF1 (24, 27, 28) .
The human substitution is not conservative (E325K), although it is on the same amino acid residue as the mutation of the Nan mice. This charge change on the protein:DNA interface suggests that the consequences for the organism would be much more serious than for the Nan mutation.
To date, only seven patients suffering from CDA type IV have been described (25, 26, (29) (30) (31) (32) (33) (34) (35) (36) (37) . In general, CDAs are a heterogeneous group of rare hereditary diseases. The CDA type IV is an autosomal dominant inherited blood disorder (26) characterized by ineffective erythropoiesis and distinct morphological anomalies in the erythroid compartment (blood and bone marrow), such as multinucleated erythroblasts, (38-40), euchromatin areas connecting the nuclear membrane, atypical cytoplasmic inclusions, and intercellular bridges (26, 31) . In addition, non-erythroid phenotypes such as growth retardation and disturbance in organ development, particularly urogenital anomalies, are manifested in some of these patients (26, 29) .
In the long run, we are interested in illuminating the molecular mechanism underlying CDA type IV disease and the involvement of mutated CDA-KLF1 in the phenotype. As an essential step towards this ultimate goal we determined the consensus binding site for this mutant. For this purpose we used a CASTing (Cyclic Amplification and Selection of Targets) (41-44) technique, which we combined with next generation sequencing (45). The identified binding motif was verified by gel retardation assays, where we followed complex formation with the newly determined sites. Next, reporter gene assays allowed us to verify transcriptional functionality of these sites.
Our findings reveal that CDA-KLF1 recognizes and binds sites that are mutually exclusive compared to the WT-KLF1 transcription factor. These altered properties have functional consequences that may help explain some of the phenotypic changes seen in the CDA patient's erythroid cells.
Results

Identification of the CDA-KLF1 consensus DNA-binding sequence
To empirically determine the DNA binding consensus site to which CDA-KLF1 binds, first we introduced CDA mutation (E339K) to WT-KLF1, which is an equivalent of E325 position in human.
This mutation is found in the second zinc finger (ZnF2) in the "Y" position directly involved in the interactions with DNA (46,47) ( Fig.1A) . Both human and mouse KLF1 orthologues share a very high homology, with 91% identity within the zinc finger domain (Fig. 1B) . Since most of the KLF1 analyzes were performed on mice, we wanted to change only one variable and follow its effect by direct comparison with the WT and Nan-KLF1 variants. The amino acid located in the "Y" position of ZnF2 interacts with the nucleotide in the middle, 5 th position of the 9-nt long binding site (47, 48) . We started our research by analyzing this relationship. We performed gel retardation assay and followed the complex formation between KLF1 variants which differ in the "Y" position and binding sites with the altered middle 5 th position. We examined the binding ability of WT-KLF1 with glutamic acid (E) at position 339 and mutants: CDA with lysine (K) and Nan-KLF1 with aspartic (D) (Fig.1C ). As binding sites, we used natural KLF1 targets: β-globin with "T" in the middle 5 th position, p21 with "C" and E2F2 site 1 with "G" (although WT-KLF1 binds only E2F2-2 and E2F2-3 sites of E2F2 (49) ). For "A" in the middle 5 th position we have prepared an artificial E2F2-1A. To be sure where the KLF1:double stranded (ds) DNA oligo complex migrates, we added antibodies against KLF1 DNA binding domain epitope, which prevents complex formation (Fig. 1D) .
The results were very exciting (Fig. 1C, E) , showing that the CDA-KLF1 mutant was able to bind only one motif containing "G" in the middle 5 th position. At the same time, two other variants, WT-KLF1 and Nan-KLF1, were unable to bind such a motif, demonstrating the mutually exclusive preferences for binding of the tested proteins. After obtaining these results, we decided to define the binding site for CDA-KLF1 more precisely.
We performed the in vitro CASTing-Seq assay, which was combined with high-throughput sequencing to characterize the high-resolution DNA-binding specificity of the KLF1 mutant ( Fig. 2A ).
In CASTing we used purified recombinant proteins comprising the DNA binding domain (DBD) of KLF1, which consists of three zinc fingers of the C2H2 type (ZnF-KLF1). The transactivation domain contains numerous prolines that make the structure unstable and prone to degradation, rendering it impossible to use the full length protein in this assay. The DBD domain had His-and Flag-tags fused at the N-terminus, enabling its purification by His-tag affinity followed by removal of the His-tag. The resultant recombinant protein was bound via its Flag-tag to magnetic beads coated with Anti-Flag M2 monoclonal antibody and used in CASTing assay. In parallel to CDA-ZnF-KLF1, we used wild type DBD (WT-ZnF-KLF1) as a positive control, for which the consensus binding site is already known (4).
The magnetic beads alone without any protein attached served as a negative control. At first we used the library that contained 12 random nucleotides flanked by constant sequences needed for amplification. The magnetic properties of the beads allowed for a very rapid separation of the beads coated by protein with bound DNA oligonucleotides from a suspension containing unbound oligonucleotides. The remaining DNA oligonucleotides that interacted with the particular ZnF domains were PCR amplified, purified and used for the next round of the assay. We performed five such cycles.
The DNA oligonucleotides enriched after fifth cycle were sequenced by NGS Ion Torrent. The results showed that CDA-ZnF-KLF1 recognizes a very G-rich sequence, containing guanine in the middle (5 th ) position of the 9-nt binding motif (data not shown). This nucleotide is directly involved in interactions with the amino acid in position 339 of the second zinc finger of KLF1 (24, 50) . In the wildtype scenario, WT-KLF1, with glutamic acid (E) in position 339, recognizes a 5'-NGG-GC/TG-T/GGG-3' consensus site; that is, a T or C in the middle position. Thus, oligonucleotides containing G in the 5 th position were not expected to form a complex with WT-KLF1 (24) . Our results from CASTing-Seq assay suggested that the CDA mutation (E339K) alters the binding specificity of KLF1. It was in agreement with our initial observation, that CDA-KLF1 recognizes G in the middle position of binding site (Fig. 1C ). However, because of the long stretches of G repeats found in the CASTing-selected CDA-ZnF-KLF1 binding motifs, and due to Ion Torrent system limitations related to sequencing of homopolymer repeats, it was difficult to unambiguously determine the CDA-KLF1 consensus binding motif.
In order to overcome this problem we repeated the CASTing assay, but this time we applied a more accurate library. In this approach, flanking sequences surround 9-nt long DNA oligonucleotides 5'-NNN-NGN-NNN-3', which are precisely the length of binding site for three zinc fingers. In addition, we forced G in the middle position, leaving the rest random and the entire CASTing-Seq experiment was performed once again. The gradual enrichment of selected oligonucleotides from the library in cycles I, III and V DNA was monitored by EMSA assay. The EMSA complexes were formed with full length CDA-KLF1 or WT-KLF1, expressed in extracts of transfected COS-7 cells ( Fig. 2B ), which therefore verified that the CASTing oligonucleotides selected by the zinc finger domain interact with the full length proteins.
The DNA oligonucleotides obtained after final round were sequenced by Ion Torrent. The resultant ~30 000 sequences were analyzed on a Galaxy platform and then the MEME suite was applied. The final results are summarized on Fig. 2C -E. The new consensus binding site for CDA-KLF1 was determined to be 5'-NGG-GGT/G-T/GT/GT/G-3'. The data for CDA-ZnF-KLF1 were obtained in two biological repeats (Fig. 2C ). The reliability of the results is based on the positive control data (WT-ZnF-KLF1; Fig. 2D ), which are in agreement with published consensus site 5'-NGG-GC/TG-T/GGG-3' (4, 24, 27) . The thymine in first position marked with a star (Fig. 2D ) comes from flanking sequence of the library. By way of explanation, the second library of the random oligonucleotides with G fixed in the middle (5 th ) position of the motif was designed especially for CDA-ZnF-KLF1. Thus in order to be bound by WT-ZnF-KLF1, a shift has to occur to have C or T in the middle position. In such a situation the binding motif had to expand to the flanking sequence. Indeed, the consensus sequence motif for WT zinc finger domain contains C or T in the 5 th position as expected and a flanking T in the 1 st position.
The negative control, the magnetic beads alone, did not select any sequence motif; it remained random ( Fig. 2E ).
In conclusion, we have newly identified the CDA-KLF1 binding motif. It is G-rich, it has G in the middle (5 th ) position crucial for interactions with ZnF2 pos.339 of KLF1 and it shows rather high degeneracy at the 3' end of the motif. The degeneracy refers to the positions 6 th , 7 th , 8 th and 9 th on the G-rich strand that are mostly involved in interactions with ZnF1 ( Fig.2C ).
Next, we validated the in vitro selection results by EMSA assays, functional reporter assays in K562 
Analysis of the essential G in the middle (5 th ) position of binding site for CDA-KLF1
We started validating the in vitro consensus binding site for the KLF1 CDA mutant by performing a quantitative EMSA experiment and a dissociation constant measurement. The complexes were generated with an increased amount of purified, recombinant zinc finger domain for WT or CDA-KLF1, respectively ( Fig. 3 ). We monitored the formation of complexes for one of the newly determined 5'-GGG-GGG-GGG-3' site and for the β-globin binding site 5'-AGG-GTG-TGG-3', as a positive control for WT-KLF1. We measured dissociation constant (Kd) for all the possible combinations of complexes ( Fig. 3 ).
Under applied conditions the binding affinity of WT-ZnF-KLF1 to β-globin site is Kd= 547,7 ± 76,4nM and it is approximately 10-fold lower than for binding site with G in the middle position (estimated Kd ~4988nM). The situation was reversed for CDA-ZnF-KLF1, which binds 5'-GGG-GGG-GGG-3' with an affinity of Kd=695,8 ± 71,1nM, while the dissociation constant for the β-globin binding site increased dramatically to Kd approx.~237527nM ( Fig. 3A-D) . These results clearly indicate preferences in the specificity of KLF1 variants based on the middle 5 th position of the binding site.
Next, we performed a cold competition assay which additionally supports the specificity of CDA-KLF1 binding to a new site with G in the middle position ( Fig. 4 ). For this purpose we used full-length WT or CDA-KLF1 protein from transfected COS-7 extracts and performed EMSA. Complexes between CDA-KLF1 and radiolabeled dsDNA oligo with G in the middle 5 th position were effectively antagonized by cold competition with binding sites that contain middle G and are marked as E2F2-1 and 9xG ( Fig. 4 panel A, B ). In the case of WT-KLF1 complexes with radiolabeled β-globin binding site, they were replaced only with cold β-globin sites. Two other binding sites with G in the middle 5 th position, i.e. E2F2-1 and 9xG did not affect the WT-KLF1 complexes ( Fig.4 panel C) .
Both experiments indicate without a doubt that CDA-KLF1 and WT-KLF1 have mutually exclusive binding sites.
Validation of the CASTing-Seq results focusing on 3' end degeneracy of the consensus binding site
Several individual CASTing-based sequences were tested in parallel for their specificity in complex formation with CDA (E339K mutation) and with WT (E339) zinc fingers ( Fig. 5 ). We focused on testing of the 3' degeneracy of the consensus binding site and analyzed oligonucleotides differed in three nucleotides (positions 7 th , 8 th and 9 th on the G-rich strand) that are recognized and bound by zinc finger 1. Based on EMSA results we distinguished two major groups of binding sites depending on their ability of complex formation. First, the largest group consists of sites that are bound by CDA-ZnF-KLF1 and not bound by WT-Zn-KLF1 (Fig. 5A) , and a second group of sites that are not bound by either CDA nor WT-ZnF-KLF1 ( Fig. 5B ). As a positive control for WT-ZnF-KLF1 we used β-globin binding site, which has "T" in the middle 5 th position, which at the same time is not a proper site for CDA-ZnF-KLF1 ( Fig.   5C ). The results were subjected to densitometric analysis to estimate the percentage involvement of the tested oligonucleotides in interactions with the CDA or WT-ZnF recombinant domain, respectively.
We find that oligonucleotides having at least one G or T in the 3' triple nucleotide are efficiently bound by CDA-ZnF-KLF1, whereas complexes generated with oligonucleotides containing only C or A in positions 7 th -9 th are very weak, estimated below 20% (Fig. 5B ). The Kd values for the complexes support the CDA-KLF1 particular binding preferences as compared to WT-KLF1.
Analysis of the specificity of complex formation between full length of KLF1 variants (WT, CDA, and
Nan-KLF1) and radiolabeled oligonucleotides
As we could use only the DNA binding domain of KLF1 for the CASTing experiment, subsequently, we tested whether full length CDA-KLF1 is able to interact with the determined consensus binding sites.
For this purpose we chose the same individual binding sites as previously tested for the 3' degeneracy ( Fig. 5 ) and performed EMSA assays using extracts from transfected COS-7 cells expressing equivalent amounts of full length constructs ( Fig. 6 ).
Here, in parallel, we tested the specificity of recognition of these oligonucleotides by different KLF1 variants that vary in the amino acid in position 339: WT-KLF1 with E339, Nan-KLF1 with D339, and CDA-KLF1 with K339.
The oligonucleotides that have G in the middle (5 th ) position and the 3' triple nucleotide consisting of at least one T or G were bound by CDA-KLF1 ( Fig. 6A ) similarly to the zinc finger domain alone (compare Fig. 6A and 5A ). However, the oligonucleotides that have G in middle (5 th ) position of the motif but do not have any G or T in the last triple nucleotide were not bound by CDA-KLF1 (compare Fig. 6A and 5B). Neither WT-KLF1 nor Nan-KLF1 full length proteins are able to interact with binding sites containing G in the middle position on the G-rich strand in any case, which is consistent with our previous observations (24) . As a positive control for these analyses we took again β-globin binding site, which was recognize and bound by WT-KLF1 and slightly by Nan-KLF1 ( Fig. 6B ).
We conclude that the novel binding properties determined by in vitro selection with the CDA-KLF1
DBD alone are retained when tested using the full length CDA-KLF1 protein.
Next, we focused on the degenerate 6 th position of novel CDA-KLF1 consensus binding site ( Fig.   2C ). We applied gel retardation testing and monitored complex formation between KLF1 variants and radiolabeled oligonucleotides that differ in this 6 th position. We analyzed all four combinations of nucleotides and the data reveled that only G or (more weakly) T in position 6 th create a suitable binding motif for CDA-KLF1 ( Fig. 6C ). As expected, WT-KLF1 or Nan-KLF1 did not bind to any of these, as they retain G in the 5 th position that prevents the interactions.
These results clearly demonstrate that the newly determined CDA-KLF1 consensus binding site, 5'-NGG-GGT/G-T/GT/GT/G-3', crucially prefers G in the middle (5 th ) position that directly interacts with the mutated E339K residue in the CDA-KLF1 protein. In addition, this single amino acid change yields a protein with an unexpectedly high level of binding degeneracy for the sequence that interacts with zinc finger 1 of CDA-KLF1 (positions 7 th , 8 th and 9 th on G-rich strand), as well as in position 6 th . Thus, CDA-KLF1 preferentially binds sites containing G or T in the last four nucleotides of the consensus binding motif.
Functional analysis of individual CDA-KLF1 binding sites by luciferase reporter gene assays in K562 cells
To test if the newly identified consensus site for CDA-KLF1 is functional, we used a luciferase reporter gene system that provides a robust and specific readout of KLF1 activity (51) . We constructed a set of luciferase reporters where, upstream of the luciferase coding sequence with its minimal TK (thymidine kinase) promoter, we placed 6x repeated individual 9-nt long binding sites selected from CASTing ( Fig.   7 , top). We used them for co-transfection of K562 cells together with particular KLF1 variants (WT, Nan, or CDA). In our K562 cells the endogenous KLF1 is not expressed (52) thus we can easily investigate the individual activity of the KLF1 variants by measuring the activation of luciferase and monitoring the relative light units (RLUs).
Our positive control, which is a reporter containing 6x β-globin binding site 5'-AGG-GTG-TGG-3', is solely activated by WT-KLF1 but not by Nan-or CDA-KLF1, as expected ( Fig. 7A ). The negative control, which consists of the same 6x repeated β-globin site but with a thalassemia point mutation 5'-AGG-ATG-TGG-3' (53), is not activated by any KLF1 construct ( Fig. 7A ). These data demonstrate that our assay system is robust and selective.
For the functional analyses we used the same binding site sequences as for in vitro EMSA assays described above ( Fig. 5 and 6 ). To make the results more convincing, we transfected K562 cells with increasing amounts of expression plasmids carrying KLF1 variants. We find that the luciferase reporter genes are activated only from binding sites that are recognized and bound by CDA-KLF1 as proven by gel retardation assay (compare Fig. 6A with 7B). Such sites need to have G in the middle (5 th ) position of the binding motif, and the 3' end of the sequence (position 7 th , 8 th and 9 th ) has to contain at least one G or T. Neither WT-KLF1 nor Nan-KLF1 are able to activate any of studied reporter genes, because of the G in the middle position.
These results evidently show that only CDA-KLF1 is able to activate the reporter genes in a pattern totally consistent with the previous analyses and thus are entirely confirmatory with the in vitro EMSA results.
Quantitative analysis of the endogenous levels of KLF1 target genes, expressed in stable K562 cell lines with induced expression of WT-or CDA-KLF1
Next, we studied the expression level of endogenous genes that might be affected by the presence of mutant KLF1. For this purpose we prepared two stable K562 cell lines with doxycycline inducible KLF1 variants, either WT-KLF1 or CDA-KLF1. After induction, we isolated total RNA and prepared reverse transcribed cDNA for quantitative analysis. We focused on monitoring expression of known WT-KLF1 targets, notably: Lu/BCAM-basal cell adhesion molecule (Lutheran blood group), AQP1-Aquaporin 1,
E2F transcription factor. Our rationale was as follows: first, it is known that AQP1 levels are dramatically lower in samples originating from patients suffering from CDA type IV compared to healthy controls (16, 35, 54) . Expression of EPB4.2 is reduced in CDA-iPS-derived erythroblasts (37) also analysis of transcriptome of the CDA patient revealed it decreased level, as it contributes to the fragility of CDA patients' red cells membrane abnormalities (55) . Second, expression of BCAM gene is lower in individuals with the In(Lu) phenotype that is caused by a variety of KLF1 mutations that lead to its haploinsufficiency (18) . Third, expression of E2F2 is decreased in the presence of Nan-KLF1 mutation (24) . Finally, the Cdkn1B gene (p27) is directly regulated by KLF1 during late stages of differentiation, where it is critical for enucleation of erythroid precursors (56) and this process is disturbed in the presence of CDA mutation (37,55). Furthermore, we expanded our analysis for TFR2transferrin receptor 2, SLC4A1-anion transport protein (BAND3) and IL17RB-Interleukin-17 receptor B based on recently published article (55) .
Analyses of RNA expression in the induced cells ( Fig. 8A) show that AQP1 and EPB4.2 are not transactivated by CDA-KLF1 as efficiently as by WT-KLF1, resembling the data from CDA patients and in CDA-iPS-derived erythroblasts ( Fig. 8A ). On the other hand, E2F2, BCAM, Cdkn1B, TFR2, SLC4A1 and IL17RB remain activated, and to an even greater level, by the CDA variant relative to WT.
The expression of IL17RB is 8-fold higher with the presence in CDA-KLF1 than WT-KLF1 ( Fig. 8A ).
As a potential explanation, inspection of the upstream promoters and introns of these genes reveals that the regulatory regions of BCAM, Cdkn1B, E2F2, TFR2, SLC4A1 and IL17RB contain binding sites for both WT-KLF1 as well as CDA-KLF1, and thus are activated and transcribed ( Fig. 8C ). AQP1 and EPB4.2 contain sites only for WT-KLF1 that are not recognized by CDA-KLF1 (Fig. 8B ), and thus unsuitable as an activation target. Interestingly, the BCAM result suggests a resolution of paradoxical patient observations, namely that BCAM expression is not affected in CDA patients while at the same time haploinsufficient levels of KLF1 are known to adversely affect BCAM expression. Our data suggest that the presence of variant DNA binding sites recognized by CDA-KLF1 protein compensates for any drop in expression of WT-KLF1 protein.
Collectively, these results show that CDA-KLF1 consensus binding site, as determined in the CASTing-Seq experiment, are uniquely recognized, bound, and transcriptionally functional endogenously in the cell.
Discussion
Mutations of transcription factors that affect amino acids involved in direct interactions with DNA change their specificity. This leads to recognition and activation of an alternate set of genes and as a result may cause serious consequences for organisms. We have investigated such a mutation in KLF1, the essential transcription factor of erythropoiesis (reviewed in 21).
Using the in vitro CASTing method we identified a new set of sequences bound by CDA-KLF1, and based on them we defined the consensus binding site as 5'-NGG-GGT/G-T/GT/GT/G-3'. It differs from the consensus binding sites for WT-KLF1, 5'-NGG-GC/TG-T/GGG-3' and for Nan-KLF1 5'-NGG-GC/AN-T/GGG-3' as well. CDA-KLF1 binding site turns to be mutually exclusive compared to binding sites for WT-KLF1 and Nan-KLF1. It contains G in the middle (5 th ) position (underlined), whereas WT-KLF1 has C/T and Nan-KLF1 C/A. Our results are in agreement with the structural studies conducted by Carl Pabo, who analyzed the relationship between functionally important amino acids of zinc fingers and DNA sequence to which they bound (50, 57, 58) . He found that if lysine is located in position +3 of the α-helix, within the ββα structure of the middle zinc finger, it has a high affinity for guanine in the middle (5 th ) position of the 9-nt binding site (50, 57, 58) . Other research investigating YY1 and TFIIIA also described similar results, finding that lysine in zinc finger 2 of YY1 and in finger 1 of TFIIIA bound guanine (59) (60) (61) (62) . In addition, a detailed bioinformatics analysis of biochemical preferences between amino acids and bases in the DNA α-helix proves that lysine preferentially forms a strong bond with guanine (63) , that entirely support our data.
Another interesting feature of our newly determined consensus binding site for CDA-KLF1 is high degeneracy of 3'end of the motif 5'-NGG-GGT/G-T/GT/GT/G-3'. On the G-rich strand, the last four positions of the motif could contain T or G nucleotides. Both bases, guanine and thymine can have alternate molecular structures based on different locations of a particular hydrogen atom. They can generate tautomeric keto or enol forms. Both guanine and thymine can switch easily from one tautomer to another. The change affects the three-dimensional shape of the molecule that may disturb the DNA: protein interface. The degeneracy of CDA-KLF1 consensus site generates a much wider combination of recognized sites as compared to WT-KLF1 or Nan-KLF1 that likely leads to a broader range of binding affinities for less specific targets. Occurrence of high degeneracy may be a solution for a too strong binding between transcription factor and target gene, which may translate to speed of the transcriptional reaction (16) .
The results showing the CDA mutation located in ZnF2 affects binding of DNA sequence by ZnF1 were unexpected. We believe that the main reason for this effect are the high affinity of interactions between lysine (E339K) and "G" in the middle 5 th position of the 9-nt binding site. These interactions, along with the remaining interactions of ZnF2 and ZnF3 with G-rich positions 1 st -4 th of the binding site may be sufficient to effectively bind CDA-KLF1 to DNA. Thus, the E to K mutation does not so much affect the specificity of ZnF1 interaction with DNA, which rather affects the binding strength/affinity of all three ZnFs, allowing for greater freedom and higher degeneration of the DNA sequence in interactions with ZnF1. The strong interactions in the complex would make the duration of binding too long, leading to low efficient function (64) as a transcription factor.
While this manuscript was prepared, the Perkins' group published data on the consensus DNAbinding site of E325K KLF1 mutant using a different approach (65) . Their consensus binding motif is in line with ours: 5'-NGG-GA/GG-T/GGG-3'. Binding affinity data show that the affinity of CDA-KLF1 for the site containing G in the 5 th position is approximately 5-fold higher than for sites with A (65). In addition, modeling studies based on the KLF4 zinc finger/DNA structure performed on a sequence with a central GGG triplet are consistent with our observations.
We tested the biochemical specificity between CDA-KLF1 in comparison with WT and Nan-KLF1 in complex formation with our defined DNA motif. We observed that the presence of G in the middle (5 th ) position of the binding motif entirely precludes complex formation with WT or Nan-KLF1. In the presence of CDA-KLF1 we detected a variation in the intensity of generated complexes suggesting that there are a range of affinities for the individual nucleotide sequences.
Both characteristics of the newly determined CDA-KLF1 consensus site (guanine in the middle position of the motif and the 3'end degeneracy) contribute to activation of neomorphic genes by CDA-KLF1 that are never activated by WT-KLF1. In the case of Nan-KLF1, the 6 th position of the consensus binding site 5'-NGG-GC/AN-T/GGG-3' contains N that accepts any nucleotide. Such motif extends the range of recognizable binding sites relative to WT-KLF1, which only accepts G in this position. As a consequence, Nan-KLF1 activates neomorphic targets that are typically never expressed in the erythroid cells (27,28). The Nan-KLF1 mutant activates Hamp and Irf7 genes (28). This ectopic gene expression contributes to the occurrence of chronic, lifelong anemia in the heterozygote Nan/+ mice (28). We can predict that a similar situation occurs in the case of CDA-KLF1 mutant. For example, patients suffering from CDA type IV present clinical manifestations outside of the erythroid system. Short stature and problems with urinary tract and gonad development are observed (26,29). Neomorphic gene activation by CDA-KLF1 may be one explanation for these characteristics.
Since we did not have access to CDA type IV patients, as this disease is very rare and only seven cases have been described (25,26,29-37), we prepared stable K562 cell lines with dox-inducible expression constructs of WT-KLF1 or CDA-KLF1. We investigated the level of transcription for known KLF1 target genes, which have both types of binding sites for the WT and CDA-KLF1 variants in their regulatory regions (promoters and/or introns). Such coexistence of both sites in close proximity may ameliorate the final outcome of gene activation for the CDA patients, as they are heterozygote for the mutation. CDA patients do not exhibit the In(Lu) phenotype (25, 26, 36, 66) , in which activation of the Lu/BCAM gene, the antigen of the Lutheran blood group, is sensitive to haploinsufficient levels of KLF1. Our analyses suggest that in CDA patients (that are genetically CDA/+), both WT and CDA KLF1 variants are able to bind and activate Lu/BCAM gene via independent promoter binding sites for both WT-KLF1 and CDA-KLF1. This clarifies previously published observations that were not entirely explained (16, 67) . This scenario may not be unique, as we found that the E2F2 and Cdkn1B cell cycle regulator genes can be activated by both transcription factors.
It will be of interest to analyze the transcriptome of CDA type IV patients to verify that they indeed have ectopic expression of neomorphic, CDA-KLF1 activated genes. A recent study (55) shows that the genomic regions surrounding a number of the top ectopically expressed genes in a CDA patient (36) contain sites that, based on the present study, bind and are activated by CDA-KLF1 (5'-TGG-GGG-TGG-3' (Fig. 1 and 7) ). We tested some of them and the higher level of expression from CDA-KLF1 we obtained for IL17RB, that is critical for expression of IL8 (55) . Since the genes activation by CDA-KLF1 were not confirmed by ChIP assay, we may not exclude the indirect effect of the presence of KLF1 mutant. Activation of non-erythroid genes may help to explain the anomalies observed in CDA patients. It is also necessary to remember that zinc fingers of KLF1 are involved in interactions with proteins (9,68-73), such CDA mutation could disturb the interface between proteins and contribute to the pathological phenotype. 
Materials and Methods
Plasmids and molecular cloning
Cell lines, transfection, nuclear extracts isolation and western blot analysis
K562 cells were cultured in RPMI medium 1640 supplemented with 10% fetal bovine serum (Corning), 0.5% Penicillin-Streptomycin (BioShop). COS-7 cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 0.5% Penicillin-Streptomycin. All cells were cultured in a humidified incubator at 37°C in a 5% CO2 and 95% air atmosphere. To prepare protein extracts for EMSA, COS-7 cells growing on 10cm diameter dishes were transfected with 10μg of plasmids: pSG5-WT-KLF1, Nan or CDA using Lipofectamine LTX according to the manufacturer's protocol. After 48 h of incubation, crude extracts were prepared as described previously (74). For western blot analysis of Flag-tagged KLF1 variants, PVDF membranes were probed with anti-Flag-tag Monoclonal M2-Peroxidase (HRP) antibody (SIGMA) or anti-KLF1 7B2 antibody as was described (13) .
Recombinant proteins expression and purification
KLF1 Flag-tag zinc finger domains: CDA-ZnF-KLF1 and WT-ZnF-KLF1 were cloned into pMCSG7 to generate an in-frame fusion to 6x-His-Tag and TEV cleavage sites. The CDA mutation (E to K) was introduced to mouse ZnF domain in position 339 aa by site directed mutagenesis, according to manufacture protocol (Agilent Technologies). Primers for mutagenesis are listed in Table 1 .
To purified DBD of KLF1 variants the pMCSG7 plasmid containing Flag-CDA-ZnF-KLF1 and FlagWT-ZnF-KLF1 were used. BL21-CodonPlus(DE3)-RIL E. coli were transformed with these plasmids and induced with 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Bacteria were cultured in the presence of 100µM ZnCl2 to assist in protein folding for 17h at 18°C before collection.
Cell pellets were resuspended in cold lysis buffer (50mM Tris-HCL pH 8.0, 1.5M NaCl, 10% glycerol and 0.5mM TCEP) with addition of sarcosyl to final 2%. Cell lysates were sonicated for 4 minutes (2 sec ON, 20 sec OFF) and centrifuged at 30500g for 30 min at 4°C. Supernatants were diluted ten times in lysis S-2 buffer and loaded on column with Zn-resin equilibrated with lysis buffer (75). Column was washed with lysis buffer with increasing salt concentration (150mM-1.5M). Then the salt concentration was decreased to 150mM allowing for efficient, on column, TEV protease cleavage for 2h at room 
CASTing for the CDA-KLF1 consensus DNA-binding site
CASTing was performed as previously described (41,44) with some modifications. In first CASTing experiment we used the library with twelve random nucleotides: 
Electro-mobility shift assay (EMSA)
The gel retardation assay was performed as previously described (24) used to identify the KLF1 band position (7) . For quantitative measurement of dissociation constant the following concentration of recombinant WT or CDA-ZnF-KLF1 domain were used: 0, 100, 150, 500, 750, 980, 1230, 1470, 1720nM. Curves were fit using Hill Slope in GraphPad. Averaged Kd and its standard deviation were calculated based on at least two EMSA gel shifts. Oligonucleotide sequences used in EMSA are listed in Table 1 .
Reporter Gene Analysis-Dual Luciferase Assays
K562 cells seeded in 24-well plates were transfected with suitable reporter genes and increasing amount of plasmid carrying WT, Nan or CDA-KLF1 using Lipofectamine LTX. After 36h of incubation cells were lysed and assayed for luciferase activities with a dual luciferase system (Promega). Plasmid pRLTK (Renilla) Promega was included as a normalization control for transfection efficiency.
Luminescence was quantified with a luminometer (GloMax 96-microplate, Promega). The results are the average of at least three experiments performed in triplicates. 
Generation of stable K562 cell lines
RNA isolation and Real-time PCR analyses
Total RNA was extracted from stable K562 cell lines with induced expression of WT or CDA-KLF1 (C) Complex formation (shown by arrow) between KLF1 variants (WT -"E", Nan -"D" and CDA -"K") and dsDNA oligos with 4 different nucleotides in 5 th position (in red). *nonspecific band. Inset: Western blot with the expression level of KLF1 variants (2µl) used in EMSA (Fig. 1C) , loading control visualized by antibodies against GAPDH.
(D) Identification of complex formed between WT-KLF1 and dsDNA β-globin binding site by addition of antibodies (Ab) against KLF1 that prevents complex formation.
(E) Summary of the interactions between KLF1 variants and the dsDNA oligos based on EMSA (Fig. 1C ). All possible nucleotides in the 5 th position (in red) were tested. The shade of grey represents the intensity of the generated complex. (E) Summary of the interactions between KLF1 variants and the dsDNA oligos based on EMSA (Fig. 1C ). All possible nucleotides in the 5 th position (in red) were tested. The shade of grey represents the intensity of the generated complex. 
